Catalent to Increase Manufacturing Capacity at Italian Facility for J&J COVID-19 Vaccine
Under an expanded agreement with J&J, Catalent Biologics will increase manufacturing capacity at its Anagni, Italy, site to accommodate the large-scale commercial supply of Janssen’s COVID-19 vaccine.
Catalent announced on March 17, 2021 that it has expanded its partnership with Janssen Pharmaceutica NV and Janssen Pharmaceuticals, two of the Janssen Pharmaceutical Companies of Johnson & Johnson, under which Catalent Biologics will increase manufacturing capacity at its Anagni, Italy, site to accommodate the large-scale commercial supply of Janssen’s COVID-19 vaccine.
Under the terms of the expanded agreement, which also includes vial-filling, inspection, labeling, and packaging services, Catalent will fast-track the qualification and scale-up of an additional high-speed vial-filling line that is set to be operational in the fourth quarter of 2021 to support vaccine production through late 2022, Catalent said in a company press release.
“We are pleased to expand our partnership with Janssen to support demand of its COVID-19 vaccine in Europe,” said Mario Gargiulo, president, Catalent Biologics, Europe, in the press release. “Our global network of state-of-the-art biologics facilities, combined with our deep expertise in manufacturing scale-up and commercial launch, is well-suited to help provide a solution to this public health crisis.”
Source: Catalent
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
